The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Svačina MKR, Sprenger-Svačina A, Tsakmaklis A, Rüb AM, Klein I, Wüstenberg H, Fink GR, Lehmann HC, Vehreschild MJGT, Farowski F
Journal
European journal of neurology
Year
2023
Keywords:
autoimmunity, firmicutes, immune neuropathies, intestinal barrier, short-chain fatty acids (SCFA)
BACKGROUND AND PURPOSE: The gut microbiome is involved in autoimmunity. Data on its composition in chronic inflammatory demyelinating polyneuropathy (CIDP), the most common chronic autoimmune disorder of peripheral nerves, are currently lacking. METHODS: In this monocentric exploratory pilot study, stool samples were prospectively collected from 16 CIDP patients (mean age 58 ± 10 years, 25% female) before and 1 week after administration of intravenous immunoglobulin (IVIg). Gut microbiota were analyzed via bacterial 16S rRNA gene sequencing and compared to 15 age-matched healthy subjects (mean age 59 ± 15 years, 66% female). RESULTS: The gut microbiota of CIDP patients showed an increased alpha-diversity (p = 0.005) and enrichment of Firmicutes, such as Blautia (p = 0.0004), Eubacterium hallii (p = 0.0004), or Ruminococcus torques (p = 0.03), and of Actinobacteriota (p = 0.03) compared to healthy subjects. IVIg administration did not alter the gut microbiome composition in CIDP in this short-term observation (p = 0.95). CONCLUSIONS: The gut microbiome in IVIg-treated CIDP shows distinct features, with increased bacterial diversity and enrichment of short-chain fatty acid producing Firmicutes. IVIg had no short-term impact on the gut microbiome in CIDP patients. As the main limitation of this exploratory pilot study was small cohort size, future studies also including therapy-naïve patients are warranted to verify our findings and to explore the impact of long-term IVIg treatment on the gut microbiome in CIDP.
Experiment 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Subjects
- Location of subjects
- Germany
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Chronic inflammatory demyelinating polyneuropathy chronic inflammatory demyelinating polyneuropathy,chronic inflammatory demyelinating polyradiculoneuropathy,CIDP,GBS,Guillain-Barre syndrome, familial,polyneuropathy, inflammatory demyelinating, acute,polyneuropathy, inflammatory demyelinating, chronic,Chronic inflammatory demyelinating polyneuropathy
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy Controls (HC)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- CIDP patients (Chronic inflammatory demyelinating polyneuropathy)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients who have been diagnosed with Chronic inflammatory demyelinating polyneuropathy
- Group 0 sample size Number of subjects in the control (unexposed) group
- 15
- Group 1 sample size Number of subjects in the case (exposed) group
- 16
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 6 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
- Matched on Factors on which subjects have been matched on in a case-control study
- age
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Source: Fig-1a and c
Description: Linear discriminant analysis (LDA) effect size of the gut microbiota of healthy subjects (HC) and chronic inflammatory demyelinating polyneuropathy (CIDP) patients of bacterial at phylum, order and family level
Abundance in Group 1: increased abundance in CIDP patients (Chronic inflammatory demyelinating polyneuropathy)
Revision editor(s): Aiyshaaaa, Svetlana up
Signature 2
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Source: Fig-1a and c
Description: Linear discriminant analysis (LDA) effect size of the gut microbiota of healthy subjects (HC) and chronic inflammatory demyelinating polyneuropathy (CIDP) patients of bacterial at phylum, order and family level
Abundance in Group 1: decreased abundance in CIDP patients (Chronic inflammatory demyelinating polyneuropathy)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroidaceae | ||
| Barnesiellaceae | ||
| Marinifilaceae | ||
| Rikenellaceae | ||
| Pseudomonadota |
Revision editor(s): Aiyshaaaa
Experiment 2
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Differences from previous experiment shown
Subjects
Lab analysis
Statistical Analysis
- Statistical test
- Mann-Whitney (Wilcoxon)
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- Not specified
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Source: Table-S1
Description: Relative abundances of the gut microbiota of healthy subjects (HC) and chronic inflammatory demyelinating polyneuropathy (CIDP) patients of bacterial at family and genus level
Abundance in Group 1: increased abundance in CIDP patients (Chronic inflammatory demyelinating polyneuropathy)
Revision editor(s): Aiyshaaaa
Retrieved from "https://bugsigdb.org/w/index.php?title=36651357&oldid=197590"
